Symbolbild · KI-generiert
Replimune Group, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Replimune develops oncolytic immunotherapies based on modified herpesviruses for the treatment of cancer. The therapies are injected directly into tumours and are designed both to destroy the tumour itself and to trigger a systemic immune response. The company has a product (Vusolimogene Oderparepvec) in advanced clinical development for melanoma.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Replimune Group, Inc. | REPL | NASDAQ | 941 Mio. USD |
| Adlai Nortye Ltd. | ANL | NASDAQ | 947 Mio. USD |
| Janux Therapeutics, Inc. | JANX | NASDAQ | 925 Mio. USD |
| InMode Ltd. | INMD | NASDAQ | 959 Mio. USD |
| Avalo Therapeutics, Inc. | AVTX | NASDAQ | 965 Mio. USD |
| Odyssey Therapeutics, Inc. | ODTX | NASDAQ | 909 Mio. USD |
| Jade Biosciences, Inc. | JBIO | NASDAQ | 975 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.